We have located links that may give you full text access.
Journal Article
Review
Efficacy and outcomes of antiplatelet therapy versus oral anticoagulants in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Annals of Medicine and Surgery 2024 May
BACKGROUND: Recent guidelines suggest that antiplatelet therapy (APT) is the standard of care in the absence of long-term oral anticoagulation (OAC) indications in patients post-transcatheter aortic valve replacement (TAVR). The superiority of one method over the other remains controversial.
MATERIALS AND METHODS: Several databases, including MEDLINE, Google Scholar, and EMBASE, were electronically searched. The primary endpoint was the all-cause mortality (ACM) rate. Secondary endpoints included cardiovascular death, myocardial infarction (MI), stroke/TIA, haemorrhagic stroke, bleeding events, systemic embolism, and valve thrombosis in post-TAVR patients receiving APT and oral anticoagulants (OACs). Forest plots were generated using Review Manager version 5.4, with a p value less than 0.05 indicating statistical significance. Subgroup analysis was performed to explore potential sources of heterogeneity.
RESULTS: Twelve studies were selected. No significant differences were observed in APT and OAC group for ACM [risk ratio (RR): 0.67; 95% CI:0.45-1.01; P =0.05], cardiovascular death [RR:0.91; 95% CI:0.73-1.14; P =0.42], MI [RR:1.69; 95% CI:0.43-6.72; P =0.46], Stroke/TIA [RR:0.79; 95% CI:0.58-1.06; P =0.12], ischaemic stroke [RR:0.83; 95% CI:0.50-1.37; P =0.47], haemorrhagic stroke [RR:1.08; 95% CI: 0.23-5.15; P =0.92], major bleeding [RR:0.79; 95% CI:0.51-1.21; P =0.28], minor bleeding [RR:1.09; 95% CI: 0.80-1.47; P =0.58], life-threatening bleeding [RR:0.85; 95% CI:0.55-1.30; P =0.45], any bleeding [RR:0.98; 95% CI:0.83-1.15; P =0.78], and systemic embolism [RR:0.87; 95% CI:0.44-1.70; P =0.68]. The risk of valve thrombosis was higher in patients receiving APT than in those receiving OAC [RR:2.61; 95% CI:1.56-4.36; P =0.0002].
CONCLUSIONS: Although the risk of valve thrombosis increased in patients receiving APT, the risk of other endpoints was comparable between the two groups.
MATERIALS AND METHODS: Several databases, including MEDLINE, Google Scholar, and EMBASE, were electronically searched. The primary endpoint was the all-cause mortality (ACM) rate. Secondary endpoints included cardiovascular death, myocardial infarction (MI), stroke/TIA, haemorrhagic stroke, bleeding events, systemic embolism, and valve thrombosis in post-TAVR patients receiving APT and oral anticoagulants (OACs). Forest plots were generated using Review Manager version 5.4, with a p value less than 0.05 indicating statistical significance. Subgroup analysis was performed to explore potential sources of heterogeneity.
RESULTS: Twelve studies were selected. No significant differences were observed in APT and OAC group for ACM [risk ratio (RR): 0.67; 95% CI:0.45-1.01; P =0.05], cardiovascular death [RR:0.91; 95% CI:0.73-1.14; P =0.42], MI [RR:1.69; 95% CI:0.43-6.72; P =0.46], Stroke/TIA [RR:0.79; 95% CI:0.58-1.06; P =0.12], ischaemic stroke [RR:0.83; 95% CI:0.50-1.37; P =0.47], haemorrhagic stroke [RR:1.08; 95% CI: 0.23-5.15; P =0.92], major bleeding [RR:0.79; 95% CI:0.51-1.21; P =0.28], minor bleeding [RR:1.09; 95% CI: 0.80-1.47; P =0.58], life-threatening bleeding [RR:0.85; 95% CI:0.55-1.30; P =0.45], any bleeding [RR:0.98; 95% CI:0.83-1.15; P =0.78], and systemic embolism [RR:0.87; 95% CI:0.44-1.70; P =0.68]. The risk of valve thrombosis was higher in patients receiving APT than in those receiving OAC [RR:2.61; 95% CI:1.56-4.36; P =0.0002].
CONCLUSIONS: Although the risk of valve thrombosis increased in patients receiving APT, the risk of other endpoints was comparable between the two groups.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app